Mir-34: A New Weapon Against Cancer?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci USA., 99, 15524, 10.1073/pnas.242606799
Volinia, 2006, A microRNA expression signature of human solid tumors defines cancer gene targets, Proc Natl Acad Sci USA., 103, 2257, 10.1073/pnas.0510565103
Croce, 2009, Causes and consequences of microRNA dysregulation in cancer, Nat Rev Genet, 10, 704, 10.1038/nrg2634
Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702
Garzon, 2010, Targeting microRNAs in cancer: rationale, strategies and challenges, Nat Rev Drug Discov, 9, 775, 10.1038/nrd3179
Ling, 2013, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nat Rev Drug Discov, 12, 847, 10.1038/nrd4140
Lionetti, 2013, Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia, Clin Cancer Res., 19, 3130, 10.1158/1078-0432.CCR-12-2043
Negrini, 2014, microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters, Clin Cancer Res., 20, 4141, 10.1158/1078-0432.CCR-13-2497
Esquela-Kerscher, 2006, Oncomirs - microRNAs with a role in cancer, Nat Rev Cancer, 6, 259, 10.1038/nrc1840
Dimopoulos, 2013, Aberrant microRNA expression in multiple myeloma, Eur J Haematol, 91, 95, 10.1111/ejh.12124
Tagliaferri, 2012, Promises and challenges of MicroRNA-based treatment of multiple myeloma, Curr Cancer Drug Targets, 12, 838, 10.2174/156800912802429355
Amodio, 2013, Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma, Expert Opin Biol Ther, 13 (suppl. 1), S125, 10.1517/14712598.2013.796356
Rossi, 2013, From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario, Curr Drug Targets, 14, 1144, 10.2174/13894501113149990186
Rossi, 2014, MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches, Curr Pharm Biotechnol, 15, 459, 10.2174/1389201015666140519104743
Tutar, 2014, MicroRNAs and Cancer; an Overview, Curr Pharm Biotechnol, 15, 430, 10.2174/1389201015666140519095304
Rolfo, 2014, Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer, Curr Pharm Biotechnol, 15, 475, 10.2174/1389201015666140519123219
Thorsen, 2012, The therapeutic potential of microRNAs in cancer, Cancer J, 18, 275, 10.1097/PPO.0b013e318258b5d6
Bader, 2012, miR-34 - a microRNA replacement therapy is headed to the clinic, Front Genet, 3, 120, 10.3389/fgene.2012.00120
Bovell, 2013, Clinical implications of microRNAs in cancer, Biotech HistoChem., 88, 388, 10.3109/10520295.2013.788735
Amodio, 2012, DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma, Oncotarget, 3, 1246, 10.18632/oncotarget.675
Amodio, 2012, miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1, Cell Death Dis, 3, e436, 10.1038/cddis.2012.175
Rossi, 2013, miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease, J Cell Physiol, 228, 1506, 10.1002/jcp.24306
Leone, 2013, Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth, Clin Cancer Res., 19, 2096, 10.1158/1078-0432.CCR-12-3325
Di Martino, 2013, In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma, Oncotarget, 4, 242, 10.18632/oncotarget.820
Amodio, 2013, miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells, Cell Cycle, 12, 3650, 10.4161/cc.26585
Leotta, 2014, A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro, J Cell Physiol, 229, 2106, 10.1002/jcp.24669
Raimondi, 2014, Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity, Oncotarget, 5, 3039, 10.18632/oncotarget.1747
Suzuki, 2012, DNA methylation and microRNA dysregulation in cancer, Mol Oncol, 6, 567, 10.1016/j.molonc.2012.07.007
Hermeking, 2010, The miR-34 family in cancer and apoptosis, Cell Death Differ, 17, 193, 10.1038/cdd.2009.56
Di Martino, 2014, In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma, PLoS ONE., 9, e90005, 10.1371/journal.pone.0090005
Di Martino, 2012, Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence, Clin Cancer Res., 18, 6260, 10.1158/1078-0432.CCR-12-1708
Iliou, 2014, Impaired DICER1 function promotes stemness and metastasis in colon cancer, Oncogene, 33, 4003, 10.1038/onc.2013.398
Liu, 2011, The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nat Med, 17, 211, 10.1038/nm.2284
Nalls, 2011, Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells, PLoS ONE., 6, e24099, 10.1371/journal.pone.0024099
Stankevicins, 2013, MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells, Radiat Oncol, 8, 231, 10.1186/1748-717X-8-231
Guessous, 2010, microRNA-34a is tumor suppressive in brain tumors and glioma stem cells, Cell Cycle, 9, 1031, 10.4161/cc.9.6.10987
Li, 2010, Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea, BMC Genomics, 11, 609, 10.1186/1471-2164-11-609
Basak, 2013, The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression, PLoS ONE., 8, e73195, 10.1371/journal.pone.0073195
Kofman, 2013, microRNA-34a promotes DNA damage and mitotic catastrophe, Cell Cycle, 12, 3500, 10.4161/cc.26459
De Antonellis, 2014, Early Targets of miR-34a in Neuroblastoma, Mol Cell Proteomics, 13, 2114, 10.1074/mcp.M113.035808
Rothe, 2014, The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells, Blood, 123, 3622, 10.1182/blood-2013-07-516807
Li, 2009, MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes, Cancer Res., 69, 7569, 10.1158/0008-5472.CAN-09-0529
Pang, 2010, MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells, Carcinogenesis, 31, 1037, 10.1093/carcin/bgq066
de Antonellis, 2011, MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma, PLoS ONE., 6, e24584, 10.1371/journal.pone.0024584
Bu, 2013, A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells, Cell Stem Cell, 12, 602, 10.1016/j.stem.2013.03.002
Winton, 2013, miR-34a sets the “sweet spot” for notch in colorectal cancer stem cells, Cell Stem Cell, 12, 499, 10.1016/j.stem.2013.04.018
Yamamura, 2012, MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells, PLoS ONE., 7, e29722, 10.1371/journal.pone.0029722
Yan, 2012, MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo, PLoS ONE., 7, e33778, 10.1371/journal.pone.0033778
Li, 2009, miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells, Cancer Lett, 275, 44, 10.1016/j.canlet.2008.09.035
Tanaka, 2013, Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells, Oncol Rep, 29, 2169, 10.3892/or.2013.2351
Zhang, 2014, MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET., PLoS ONE., 9, e91546, 10.1371/journal.pone.0091546
Menges, 2014, Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis, Cancer Res., 74, 1261, 10.1158/0008-5472.CAN-13-2062
Siemens, 2013, Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness, Oncotarget, 4, 1399, 10.18632/oncotarget.1202
Zhao, 2013, MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line, DNA Cell Biol., 32, 699, 10.1089/dna.2013.2130
Wu, 2013, MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression, Int J Med Sci, 10, 676, 10.7150/ijms.5528
Duan, 2013, Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway, J Radiat Res., 54, 611, 10.1093/jrr/rrs136
Yang, 2014, MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment, Technol Cancer Res Treat, 13, 77, 10.7785/tcrt.2012.500364
Lou, 2013, Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model, J Mol Med, 91, 715, 10.1007/s00109-012-0985-x
Li, 2013, MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1, Clin Exp Med, 13, 109, 10.1007/s10238-012-0186-5
Wang, 2013, microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status, Cancer Biother Radiopharm, 28, 45, 10.1089/cbr.2012.1218
Shen, 2012, MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin, Med Oncol, 29, 2473, 10.1007/s12032-011-0156-x
Cao, 2014, miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway, Tumour Biol., 35, 1287, 10.1007/s13277-013-1171-7
Kumar, 2012, Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis, PLoS ONE., 7, e37601, 10.1371/journal.pone.0037601
Kashat, 2012, Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness, Am J Transl Res., 4, 432
Yang, 2012, TGF-ß-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma, Cancer Cell, 22, 291, 10.1016/j.ccr.2012.07.023
Mandke, 2012, MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame, PLoS ONE., 7, e42034, 10.1371/journal.pone.0042034
Okada, 2014, A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression, Genes Dev, 28, 438, 10.1101/gad.233585.113
Mackiewicz, 2011, Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA, Breast Cancer Res Treat, 130, 663, 10.1007/s10549-011-1690-0
Mudduluru, 2011, Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer, Oncogene, 30, 2888, 10.1038/onc.2011.13
Vo, 2011, The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs, RNA Biol., 8, 817, 10.4161/rna.8.5.16041
Muppala, 2013, CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a, PLoS ONE., 8, e59563, 10.1371/journal.pone.0059563
Kim, 2012, A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH, Biochem Biophys Res Commun, 418, 682, 10.1016/j.bbrc.2012.01.077
Heinemann, 2012, Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D, Cancer Res., 72, 460, 10.1158/0008-5472.CAN-11-1977
Yin, 2013, miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme, Oncogene, 32, 1155, 10.1038/onc.2012.132
Kaller, 2011, Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis, Mol Cell Proteomics, 10, 010462, 10.1074/mcp.M111.010462
Zhao, 2013, TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.), Mol Ther, 21, 1678, 10.1038/mt.2013.148
Garofalo, 2013, MiR-34a/c-Dependent PDGFR-a/ß Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer, PLoS ONE., 8, e67581, 10.1371/journal.pone.0067581
Jin, 2014, miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells, Tumour Biol., 35, 1503, 10.1007/s13277-013-1207-z
Davis, 2008, SMAD proteins control DROSHA-mediated microRNA maturation, Nature, 454, 56, 10.1038/nature07086
Yamagata, 2009, Maturation of microRNA is hormonally regulated by a nuclear receptor, Mol Cell, 36, 340, 10.1016/j.molcel.2009.08.017
Hau, 2012, CD95 is part of a let-7/p53/miR-34 regulatory network, PLoS ONE., 7, e49636, 10.1371/journal.pone.0049636
Rücker, 2013, Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance, Leukemia, 27, 353, 10.1038/leu.2012.208
Ma, 2013, MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation, PLoS ONE., 8, e72383, 10.1371/journal.pone.0072383
Craig, 2011, Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1, Blood, 117, 6227, 10.1182/blood-2010-10-312231
Siemens, 2011, miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions, Cell Cycle, 10, 4256, 10.4161/cc.10.24.18552
Rokavec, 2014, IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis, J Clin Invest, 124, 1853, 10.1172/JCI73531
Silber, 2012, miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis, PLoS ONE., 7, e33844, 10.1371/journal.pone.0033844
Zhao, 2014, In-depth analysis shows synergy between erlotinib and miR-34a, PLoS ONE., 9, e89105, 10.1371/journal.pone.0089105
Li, 2012, MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1, Arch Med Res., 43, 514, 10.1016/j.arcmed.2012.09.007
Vinall, 2012, MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status, Int J Cancer, 130, 2526, 10.1002/ijc.26256
Akao, 2011, Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells, Cancer Lett, 300, 197, 10.1016/j.canlet.2010.10.006
Kojima, 2010, MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms, Prostate, 70, 1501, 10.1002/pros.21185
Ogawa, 2012, miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis, Cancer Sci, 103, 1737, 10.1111/j.1349-7006.2012.02338.x
Nakatani, 2012, miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy, J Pathol, 226, 796, 10.1002/path.3007
Kutay, 2006, Downregulation of miR-122 in the rodent and human hepatocellular carcinomas, J Cell BioChem., 99, 671, 10.1002/jcb.20982
Pogribny, 2008, Differential expression of microRNAs during hepatocarcinogenesis induced by methyl deficiency in rats, Nutr Rev, 66 (suppl. 1), S33, 10.1111/j.1753-4887.2008.00064.x
Guo, 2013, Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a, Mol Cell BioChem., 382, 103, 10.1007/s11010-013-1723-6
Roy, 2012, Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF., J Hematol Oncol, 5, 58, 10.1186/1756-8722-5-58
Kang, 2013, Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines, J Biol Chem., 288, 27343, 10.1074/jbc.M113.490482
Ji, 2012, Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells, Int J Cancer, 131, 2668, 10.1002/ijc.27549
Xia, 2012, Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells, Curr Drug Targets, 13, 1750, 10.2174/138945012804545597
Tomosugi, 2012, Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor, Cancer Sci, 103, 2139, 10.1111/cas.12012
Chiyomaru, 2013, Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR, PLoS ONE., 8, e70372, 10.1371/journal.pone.0070372
Hui, 2012, MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis, Breast Cancer Res., 14, R80, 10.1186/bcr3194
Chakrabarti, 2013, Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells, Neurochem Res., 38, 420, 10.1007/s11064-012-0936-5
Chakrabarti, 2012, Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells, Brain Res., 1454, 1, 10.1016/j.brainres.2012.03.017
Kota, 2009, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, Cell, 137, 1005, 10.1016/j.cell.2009.04.021
Qiu, 2011, Creating a flexible multiple microRNA expression vector by linking precursor microRNAs, Biochem Biophys Res Commun, 411, 276, 10.1016/j.bbrc.2011.06.123
Calimeri, 2011, A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells, Leukemia, 25, 707, 10.1038/leu.2010.300
Tassone, 2012, Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma, Curr Cancer Drug Targets, 12, 814, 10.2174/156800912802429292
Li, 2012, Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion, Mol Ther, 20, 2326, 10.1038/mt.2012.201
Kasinski, 2012, miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma, Cancer Res., 72, 5576, 10.1158/0008-5472.CAN-12-2001
Iqbal, 2014, miR-34a is essential for p19(Arf)-driven cell cycle arrest, Cell Cycle, 13, 792, 10.4161/cc.27725
Ahn, 2012, ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression, J Clin Invest, 122, 3170, 10.1172/JCI63608
Wiggins, 2010, Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34, Cancer Res., 70, 5923, 10.1158/0008-5472.CAN-10-0655
Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol Ther, 19, 1116, 10.1038/mt.2011.48
Chen, 2010, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy, Mol Ther, 18, 1650, 10.1038/mt.2010.136
Pramanik, 2011, Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice, Mol Cancer Ther, 10, 1470, 10.1158/1535-7163.MCT-11-0152
Corney, 2010, Frequent downregulation of miR-34 family in human ovarian cancers, Clin Cancer Res., 16, 1119, 10.1158/1078-0432.CCR-09-2642
Feinberg-Gorenshtein, 2009, Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site, Genes Chromosomes Cancer, 48, 539, 10.1002/gcc.20662
Dijkstra, 2009, 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation, Leukemia, 23, 625, 10.1038/leu.2008.264
Lodygin, 2008, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer, Cell Cycle, 7, 2591, 10.4161/cc.7.16.6533
Siemens, 2013, Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and ß-catenin predicts distant metastasis of colon cancer, Clin Cancer Res., 19, 710, 10.1158/1078-0432.CCR-12-1703
Toyota, 2008, Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer, Cancer Res., 68, 4123, 10.1158/0008-5472.CAN-08-0325
Tazawa, 2007, Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells, Proc Natl Acad Sci USA., 104, 15472, 10.1073/pnas.0707351104
Pineau, 2010, miR-221 overexpression contributes to liver tumorigenesis, Proc Natl Acad Sci USA., 107, 264, 10.1073/pnas.0907904107
Dang, 2013, Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET, PLoS ONE., 8, e61054, 10.1371/journal.pone.0061054
Gallardo, 2009, miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer, Carcinogenesis, 30, 1903, 10.1093/carcin/bgp219
Franchina, 2014, Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer, J Cell Physiol, 229, 97
Peurala, 2011, MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer, PLoS ONE., 6, e26122, 10.1371/journal.pone.0026122
Eichelser, 2013, Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression, Clin Chem., 59, 1489, 10.1373/clinchem.2013.205161
Javeri, 2013, Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis, Med Oncol, 30, 413, 10.1007/s12032-012-0413-7
Nugent, 2012, Circulating miR-34a levels are reduced in colorectal cancer, J Surg Oncol, 106, 947, 10.1002/jso.23174
Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov, 3, 406, 10.1158/2159-8290.CD-12-0429
Lee, 2013, Recent developments in nanoparticle-based siRNA delivery for cancer therapy, Biomed Res Int, 2013, 782041, 10.1155/2013/782041
Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J Control Release, 65, 271, 10.1016/S0168-3659(99)00248-5
Basile, 2012, Active targeting strategies for anticancer drug nanocarriers, Curr Drug Deliv, 9, 255, 10.2174/156720112800389089
De Rosa, 2010, Oligonucleotide delivery in cancer therapy, Expert Opin Drug Deliv, 7, 1263, 10.1517/17425247.2010.527942
Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J Control Release, 114, 100, 10.1016/j.jconrel.2006.04.014
Scognamiglio, 2014, Transferrin-conjugated SNALPs encapsulating 2’-O-methylated miR-34a for the treatment of multiple myeloma, Biomed Res Int, 2014, 217365, 10.1155/2014/217365
Deng, 2014, Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer, Biomaterials, 35, 4333, 10.1016/j.biomaterials.2014.02.006
Wang, 2014, Degradable Hyaluronic Acid/Protamine Sulfate Interpolyelectrolyte Complexes as miRNA-Delivery Nanocapsules for Triple-Negative Breast Cancer Therapy, Adv Healthc Mater.9
Tivnan, 2012, Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles, PLoS One, 7, e38129, 10.1371/journal.pone.0038129
Hu, 2013, Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model, Biomaterials, 34, 2265, 10.1016/j.biomaterials.2012.12.016
Witwer, 2010, MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response, J Immunol, 184, 2369, 10.4049/jimmunol.0902712
Dicitore, 2014, Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-? (PPAR-?): at the cross-road of pancreatic cancer cell proliferation, Biochim Biophys Acta, 1845, 42
Vitale, 2012, The PPAR-? agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-ß treated pancreatic cancer cells, Biotechnol Adv, 30, 169, 10.1016/j.biotechadv.2011.08.001